脂蛋白(a)水平与2型糖尿病发病及阿利西尤单抗治疗的修饰作用
在ODYSSEY OUTCOMES试验中,13,480例无糖尿病基线患者随访中位2.7年,1,324例发生2型糖尿病。安慰剂组基线脂蛋白(a)每低10 mg/dL,2型糖尿病风险增加(HR 1.04)。阿利西尤单抗总体对2型糖尿病发病无影响,但治疗相关脂蛋白(a)降低与风险增加相关,且与基线水平存在交互作用。
要点
- 基线脂蛋白(a)较低与2型糖尿病发病风险增加相关。
- 阿利西尤单抗总体对2型糖尿病发病无显著影响。
- 阿利西尤单抗治疗中脂蛋白(a)降低与2型糖尿病风险增加相关。
核心结论
- 在急性冠脉综合征患者中,基线脂蛋白(a)浓度与2型糖尿病发病呈负相关。
- 阿利西尤单抗对2型糖尿病发病总体呈中性效应。
- 治疗相关脂蛋白(a)降低与2型糖尿病风险增加相关,且从高基线水平降低更明显。
研究设计与样本
- ODYSSEY OUTCOMES试验中阿利西尤单抗与安慰剂对比,纳入急性冠脉综合征患者。
- 基线无糖尿病的13,480例患者中,1,324例在中位2.7年内发生2型糖尿病。
主要发现
- 基线脂蛋白(a)中位数为21.9 mg/dL。
- 安慰剂组基线脂蛋白(a)每低10 mg/dL,2型糖尿病发病风险比1.04(95% CI 1.02-1.06,P < 0.001)。
- 阿利西尤单抗使脂蛋白(a)中位降低23.2%,对2型糖尿病发病总体风险比0.95(95% CI 0.85-1.05)。
- 治疗与基线脂蛋白(a)交互作用P = 0.006:低基线时阿利西尤单抗趋于降低发病,高基线时趋于增加发病。
- 阿利西尤单抗组脂蛋白(a)每降低10 mg/dL,2型糖尿病发病风险比1.07(95% CI 1.03-1.12,P = 0.0002)。
临床怎么用
- 对接受阿利西尤单抗治疗的患者,监测脂蛋白(a)降低幅度可能有助于评估2型糖尿病风险。
- 基线脂蛋白(a)水平较低者使用阿利西尤单抗时需关注2型糖尿病发生风险。
局限性
- 这些发现是否适用于其他降低脂蛋白(a)的疗法尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor. RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data. RESULTS: Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02-1.06, P < 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85-1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment-baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03-1.12; P = 0.0002) for incident type 2 diabetes. CONCLUSIONS: In patients with acute coronary syndrome, baseline lipoprotein(a) concentration associated inversely with incident type 2 diabetes. Alirocumab had neutral overall effect on incident type 2 diabetes. However, treatment-related reductions in lipoprotein(a), more pronounced from high baseline levels, were associated with increased risk of incident type 2 diabetes. Whether these findings pertain to other therapies that reduce lipoprotein(a) is undetermined.
引用
- Schwartz GG, Szarek M, Bittner VA, et al. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care. 2021. PMID: 33722880. doi:10.2337/dc20-2842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。